Clinical Trial Update: A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CMV vaccine HB-101 in kidney transplant patients has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection
• Kidney Transplantation

Drugs mentioned

• HB-101

Snippet

Sponsor: Hookipa Biotech GmbH | Conditions: Cytomegalovirus (CMV) Infection, Kidney Transplantation | Phase 2 | Status: COMPLETED | Results posted: 2023-10-26